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risk for fungal infection related to low 
doses of steroids is minimal. Active 
surveillance, as well as analysis of 
associated risk factors, is required to 
detect concurrence of severe oppor-
tunistic infections in patients treated 
with TNF antagonists and to identify 
patients who could benefi t from these 
therapies with fewer risks.
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Infl uenza A (H5N1)
To the Editor: Novel antigenic 
subtypes of infl uenza viruses have 
been introduced periodically into the 
human population, resulting in large-
scale global outbreaks (1). Highly 
pathogenic avian infl uenza (H5N1) 
viruses reemerged in 2003. Since 
then, they have reached endemic lev-
els among poultry in several South-
east Asian countries, and across Asia, 
they have caused nearly 300 human 
infections, with a high rate of mortal-
ity (1,2). The results of many studies, 
including those for one recently con-
ducted by Dinh et al. (3), have been 
published in an effort to identify the 
source(s) and modes of transmission 
of infl uenza A (H5N1) to humans and 
to guide the control and prevention of 
infl uenza infection.
Although new data regarding 
infl uenza A (H5N1) are urgently re-
quired, scientifi c rigor must be main-
tained during research and analysis 
to prevent misidentifi cation of expo-
sures as a risk factor for the disease 
and to prevent creation of iatrogenic 
panic among the exposed popula-
tion and the scientifi c community (4). 
One point of scientifi c rigor that must 
be maintained is the use of adequate 
statistical analysis. The multivariate 
model in the study by Dinh et al. (3) 
was constructed by using a backward, 
stepwise variable selection strategy, in 
which variables with p<0.20 were in-
cluded in the initial model. However, 
such a strategy has resulted in a fi rst 
model and subsequent steps with far 
more than 10 variables per outcome 
(e.g., 28 persons with avian fl u), re-
sulting in model overfi tting (i.e., a 
statistical model that is too complex 
for the amount of data), which could 
result in imprecise estimates or spuri-
ous associations (5).
We believe that scientifi c methods 
must be meticulously applied when 
planning, executing, analyzing, and 
interpreting the results of infl uenza 
(H5N1) studies to prevent identifi ca-
tion of false risk factors for acquiring 
infection.
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In Response: Lukrafka et al. (1) 
warn against the dangers of overfi tting 
a regression model when the num-
ber of outcomes is <10 per variable, 
“which could result in imprecise esti-
mates or spurious associations.” This 
warning is valid, but it is equally im-
portant to consider the relative merits 
of multiple analysis options given the 
data available, the diffi culties in col-
lecting the data, and the objective of 
the study. The objective of our study 
(2) was to explore possible risk factors 
for human infection with infl uenza A 
(H5N1) rather than to test an explicit 
a priori hypothesis or to obtain precise 
estimates of risk. We were limited to 
a fi nite number of cases, and had we 
slavishly followed criteria to avoid 
overfi tting, we would not have run a 
regression model at all because we 
could have included only 2 variables, 
for which a stratifi ed analysis would 
have been preferable. The regression 
model was run to confi rm that the 
variables identifi ed in the bivariate 
analysis retained their importance in 
the context of other variables; it was 
not intended to confi rm or refute an 
a priori hypothesis, to be a predictive 
model, or to obtain precise and adjust-
ed measures of risk. Despite the sam-
ple size limitations, we felt that look-
ing at independence in a multivariable 
analysis was still valuable.
We explicitly acknowledge the 
limitations imposed by a small study 
size and were cautious in our inter-
pretation, stating that the fi ndings are 
the “basis for formulating new hy-
potheses.” The wide confi dence inter-
vals clearly indicate the low level of 
precision. The 3 variables in the fi nal 
regression model were all statistically 
signifi cant in bivariate analysis, and 
we do not believe they are spurious 
associations arising solely from an 
overfi tted regression model.
Peter Horby*  
*National Institute for Infectious and Tropi-
cal Diseases, Hanoi, Vietnam
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Ilheus Virus Isolate 
from a Human, 
Ecuador
To the Editor: Ilheus virus 
(ILHV) (genus Flavivirus in the Nta-
ya antigenic complex) is most closely 
related to Rocio virus. However, anti-
bodies produced during ILHV infec-
tion cross-react in serologic assays to 
other fl avivirus antigens, and ILHV 
was originally classifi ed in the Japa-
nese encephalitis antigenic complex 
(1–3). ILHV is transmitted in an en-
zootic cycle between birds and mos-
quitoes. Since the fi rst isolation of 
ILHV from a pool of Aedes spp. and 
Psorophora spp. mosquitoes collected 
in 1944 at Ilheus City, on the east-
ern coast of Brazil (4), isolates have 
been obtained in Central and South 
America and Trinidad, primarily from 
Psorophora ferox mosquitoes (5,6). 
ILHV is not associated with epidemic 
disease and has been only sporadical-
ly isolated from humans (5,7–9). The 
clinical spectrum of human infections 
documented by virus isolation ranges 
from asymptomatic to signs of central 
nervous system involvement sugges-
tive of encephalitis. Most commonly, 
patients exhibit a mild febrile illness 
accompanied by headache, myalgia, 
arthralgia, and photophobia, symptoms 
that may result in clinical diagnosis of 
dengue, Saint Louis encephalitis, yel-
low fever, or infl uenza (7). Laboratory 
diagnosis of ILHV infection may be 
diffi cult, unless a virus isolate can be 
obtained, because of the cross-reactiv-
ity in serologic assays to other fl avivi-
ruses that circulate in the same area, 
such as Rocio, dengue, yellow fever, 
and Saint Louis encephalitis viruses.
On March 1, 2004, after 4 days 
of symptoms, a 20-year-old male sol-
dier stationed in Lorocachi, Ecuador, 
was admitted to the Hospital de la IV 
División del Ejercito “Amazonas” in 
Puyo, Ecuador. Lorocachi is in the 
Amazonian province of Pastaza, of 
which Puyo is the capital. The patient 
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